

**MINUTES OF THE 23rd MEETING OF
ANGLO CELTIC COOPERATIVE ONCOLOGY GROUP
INTENSIVE CHEMOTHERAPY FOR HIGH RISK BREAST CANCER**

Friday 21st October 2005

PRESENT:

Prof RCF Leonard

Chair

Dr D Adamson
Dr D Cameron
Dr P Canney
Dr H Earl
Dr C Gallagher
Dr A Humphreys
Dr J Lee
Dr J MacKay
Dr C Macmillan
Dr M Mano
Dr J Mansi
Dr M Quigley
Dr R Stein
Mr A Thompson
Dr M Verrill

Dundee
Edinburgh
Glasgow (Beatson)
Addenbrookes
Barts
Middlesborough
Newcastle
UCL
Northampton
Glasgow (Beatson)
St Georges
Romford
UCLH
Dundee
Newcastle

Fiona Campbell
Leanne Ferrigan
Liz Foster
Michelle McLinden

ISD Edinburgh
ISD Edinburgh
ISD Edinburgh (note taker)
ISD Edinburgh

Charles Brigden
Isobel Greenfield
Tim Habeshaw
Sally Lewis
Claire Madden
Pam Muscutt
Sarah Reynia
Suzanne Robinson
Matt Scullion

Amgen
Roche
Roche
Lilly
Lilly
Amgen
Amgen
Sanofi-Aventis
Novartis

**MINUTES OF THE 23rd MEETING OF
ANGLO CELTIC COOPERATIVE ONCOLOGY GROUP
INTENSIVE CHEMOTHERAPY FOR HIGH RISK BREAST CANCER**

Friday 21st October, RIBA, London

	ACTION
<p>1. Apologies. RL conveyed apologies to the meeting. A list of these may be obtained, if required, from LF.</p>	LF
<p>2. Minutes of the last meeting, and Matters Arising</p> <ul style="list-style-type: none"> • Nothing more had been reported on IBDIS. • Anglo Celtic I number of events were supplied by LF and Ann Yellowlees. There seems to be an interesting difference in distant recurrence which will be monitored. • Biological Sub Studies – Blocks still being collected. 	
<p>3. Educational Meeting JC will host the next Educational Meeting in Dublin ie 5th MAY 2006. JC suggested it should be a forum for 3-4 companies focussing on new drugs and CB had stated at the last meeting that Amgen would like to be one of the companies supporting this meeting. JC would liaise with LF as regards the meeting. There will be a business meeting probably the night before the main meeting – to be decided.</p>	JC LF
<p>4. Adjuvant chemotherapy following primary medical therapy and surgery in poor risk breast cancer patients “CARAT” Anglo Celtic VIII Dr Max Mano presented the trial on behalf of collaborators. There was a long debate about the protocol but this ended up with capecitabine x 4 with concomitant RT and close safety monitoring as the favoured option. Patient numbers would be 3000 in order to detect a difference of 5%. Fiona Campbell from ISD Edinburgh will be the statistician on the project. RL will take the slides to the BIG meeting. MM will revise the protocol and LF will send it out to the Group ASAP. MM is moving to Belgium and, hopefully, we will be able to run parallel trials. JM, CG and Anne Robinson will continue to collaborate in the UK.</p>	RL MM,LF

<p>5. PCI trial – Anglo Celtic VII External referees comments were favourable. CTAAC had delayed their meeting. PC will also put in a TRICC application.</p>	<p>PC</p>
<p>6. Will Weekly Win – Anglo Celtic IV MV presented the accrual figures of 495 patients out of 600 to date. The DMC had met in September and were shown an interim analysis on the first 200 patients. They had asked the Group to go up to the 600 patients. All patients are doing quite well and are similar to the patient population in the Seidman study – may do a meta analysis. The Group were encouraged to try and reach the target. Jo Lee (Research Fellow) has 200 blood samples and the Group agreed to let her have access to blinded data. It was decided to set an end date of APRIL 1st . MV will write to the DMC. Leanne Ferrigan will get as much data as possible.</p>	<p>MV Le Fe</p>
<p>7. TACT II Dave Cameron reported that TACT II was very nearly open. The centres who have expressed an interest will be opened in waves to avoid an overwhelming amount of accrual at the start. RL pointed out that good accruing centres would start off ‘behind the grid’ through no fault of their own if their ethics/R&D was slow whereas weaker recruiting centres with efficient R&D had an unfair advantage. DC said he would re-think this plan.</p>	
<p>8. HERA Dave Cameron reported that HERA had published. The latest amendment had gone through and that follow-up was important.</p>	
<p>9. Neo-Tango Helena Earl reported there are now 55 centres with LREC approval, 22 centres have signed contracts and 11 centres are actively recruiting. 54 patients have been randomised. The tissue collection is going well</p>	
<p>10. Biologocal Sub Studies Group Nothing to report</p>	
<p>11. MINDACT This is an EORTC/BIG trial on node –ve breast cancer. RL asked the Group if they would become involved. There was a long discussion on the politics of this trial, and some of the Group have reservations. LF has forwarded the link to the MINDACT website www.eortc.be/services/unit/mindact/</p>	
<p>12. OPTION – Anglo Celtic V RL reported that accrual was very poor to this trial. After some discussion it was agreed to add ER +ve and lymphoma patients to the trial. This will have to be discussed with trial management committee.</p>	<p>RL</p>

There is also a film of RL talking to a patient about advantages of trial. A CD of this will be made available.	
13. WHETHER This is ongoing. ER+ves will probably be added again.	
14. ELDERLY TRIAL There was some discussion about herceptin being included in treatment for a sub-group of patients. Basic design is AC vs nothing. May be cardiotoxicity so soon after AC. Roche expressed an interest. It was agreed that RL, PC and Roche will meet in San Antonio.	RL, PC, Roche
15. SPROG – Anglo Celtic III 267 out of 400 accrued to date.	
16. Oxford Overview and Follow-up LF had attended the Oxford Overview meeting and this had been postponed until 2006 due to lack of new data. Ann Yellowlees will send in the Anglo Celtic I and II data on behalf of the Group. LF reported that on prompting some centres for long term follow up for Anglo Celtic I there was just a note in reply to say that the patients had been discharged. The Group agreed that their research nurses/data managers should attempt to contact GP's and find any information available. Investigators are responsible for this follow up. DC raised the problem of resources from NCRI for follow up and it was agreed that RL should write to NCRI on behalf of the Group. Trials Units should also be encouraged to write.	AY ALL RL
17. Finances DC reported he had £3,500 left in the Anglo Celtic account at the University of Edinburgh. LF holds the bulk of the Anglo Celtic funds and will email the finance report to the Group	LF
18. Next Meeting 5th May 2006 in DUBLIN	

Note to minutes:- LF has sent round the financial report.